Anti-PD-1 Therapy May Benefit Patients with Hematologic Malignancies

Researchers report that PD-1/PD-L1 monoclonal blocking antibody allows T cells to remain active and fight malignant evolution, subsequently preventing tumor resistance.

Source: CancerNetwork - March 7, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news